Page last updated: 2024-12-08
hydroxytriamterene sulfate ester
Description
Research Excerpts
Clinical Trials
Roles
Classes
Pathways
Study Profile
Bioassays
Related Drugs
Related Conditions
Protein Interactions
Research Growth
Market Indicators
Description
hydroxytriamterene sulfate ester: RN given refers to parent cpd [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
Cross-References
| ID Source | ID |
|---|---|
| PubMed CID | 162951 |
| CHEMBL ID | 3544822 |
| MeSH ID | M0086920 |
Synonyms (24)
| Synonym |
|---|
| 4-(2,4,7-triaminopteridin-6-yl)phenol hydrogen sulfate (ester) |
| hydroxytriamterene sulfate |
| sulfuric acid, 4-(2,4,7-triamino-6-pteridinyl)phenyl ester |
| phenol, 4-(2,4,7-triaminopteridin-6-yl)-, hydrogen sulfate (ester) |
| hydroxytriamterene sulfate ester |
| [4-(2,4,7-triaminopteridin-6-yl)phenyl] hydrogen sulfate |
| 61867-18-3 |
| hydroxytriamterene sulfuric acid ester |
| phenol, 4-(2,4-diamino-6-pteridinyl)-, hydrogen sulfate (ester) |
| p-hydroxytriamterene sulfate |
| 7634cq9zjd , |
| 1476-48-8 |
| unii-7634cq9zjd |
| FT-0670189 |
| 4-hydroxytriamterene sulfate |
| p-hydroxytriamterene sulfuric acid ester |
| phenol, p-(2,4,7-triamino-6-pteridinyl)-hydrogen sulfate (ester) |
| CHEMBL3544822 |
| 4-hydroxy triamterene sulfate,sodium salt |
| DTXSID10933158 |
| 4-(4-amino-2,7-diimino-1,2,3,7-tetrahydropteridin-6-yl)phenyl hydrogen sulfate |
| p-hydroxy triamterene sulfate |
| Q27266436 |
| para-hydroxy triamterene sulfate |
Research Excerpts
Pharmacokinetics
| Excerpt | Reference | Relevance |
|---|---|---|
| " Therefore, the aim of this study was to examine the dose linearity of TA and the pharmacokinetic and pharmacodynamic interaction of triamterene and hydrochlorothiazide." | ( Pharmacokinetics and pharmacodynamics of triamterene and hydrochlorothiazide and their combination in healthy volunteers. Knauf, H; Möhrke, W; Mutschler, E, 1997) | 0.3 |
Bioavailability
| Excerpt | Reference | Relevance |
|---|---|---|
| " Comparing these data with results after oral application of TA the bioavailability of TA was 52% and the extent of absorption 83%." | ( Pharmacokinetics of triamterene. Gilfrich, HJ; Knauf, H; Möhrke, W; Mutschler, E; Völger, KD, 1983) | 0.27 |
Dosage Studied
| Excerpt | Relevance | Reference |
|---|---|---|
| " In the controls the average plasma concentration of triamterene during a dosage interval was 45 +/- 8 ng/ml and that of hydroxy-triamterene sulfate, an active metabolite of triamterene, was 967 +/- 177 ng/ml." | ( Kinetics and dynamics of triamterene at steady-state in patients with cirrhosis. Dao, MT; Villeneuve, JP, 1988) | 0.27 |
| "In this study we compared the absorption and disposition of two commonly used combination formulations of hydrochlorothiazide and triamterene (Dyazide and Maxzide) in 48 patients with essential hypertension after dosing with each formulation to steady state." | ( Absorption and disposition of two combination formulations of hydrochlorothiazide and triamterene: influence of age and renal function. Benet, LZ; Blume, C; Clark, TS; Lin, E; Thornhill, MD; Upton, RA; Williams, RL, 1986) | 0.27 |
| " The bioavailability of different dosage forms was correlated with in vitro tests." | ( Pharmacokinetics of triamterene. Gilfrich, HJ; Knauf, H; Möhrke, W; Mutschler, E; Völger, KD, 1983) | 0.27 |
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
Research
Studies (13)
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 8 (61.54) | 18.7374 |
| 1990's | 3 (23.08) | 18.2507 |
| 2000's | 2 (15.38) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
Market Indicators
Research Demand Index: 11.37
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (11.37) All Compounds (24.57) |
Study Types
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 1 (7.14%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 13 (92.86%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||